About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company pioneering precision psychiatry through biology-driven medicine development. The company is disrupting the traditional trial-and-error approach to treating neuropsychiatric conditions by measuring brain biology to predict clinical response and match patients with treatments most likely to benefit them. Built on 15 years of field-leading neurobiology research, Alto develops novel medicines designed to target core brain processes in people suffering from neuropsychiatric conditions. The company's initial focus areas include major depressive disorder, bipolar depression, and schizophrenia. Alto's precision approach enables faster and more effective treatment outcomes by identifying patient subgroups based on neurobiological markers. The team leverages deep expertise in CNS drug development and commercialization to bring alternative treatment options to patients with mental health conditions.
Mission & Story
Mission
We develop biology-driven medicines for neuropsychiatric conditions so that patients can get better faster
Clinical Focus
Medical conditions and clinical areas addressed by Alto Neuroscience.
Who It Serves
Milestones & Awards
Recent Milestones
Clinical-stage pipeline development in major depressive disorder, bipolar depression, and schizophrenia
Company Details
- Headquarters
- Mountain View, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 48 →
AbleTo
AI-powered mental health and digital therapeutics platform delivering behavioral health interventions and therapy support.
Akili
Akili Interactive creates FDA-authorized digital therapeutics delivered through video game experiences to treat cognitive impairments. Their flagship products include EndeavorRx, the first FDA-approved prescription video game for children with ADHD, and EndeavorOTC for adults with ADHD.
Alma
Alma is a mental health care platform that connects clients with therapists who accept insurance across all 50 states. The company supports both clients seeking affordable therapy and mental health providers with practice management tools and insurance credentialing.
BeMe Health
BeMe is a mobile mental health platform designed specifically for teens and young adults. The app provides a safe space for mood tracking, personalized content, live 1:1 coaching, and crisis support to improve emotional well-being and mental health.
Big Health
Big Health provides FDA-cleared digital therapeutics delivering cognitive behavioral therapy (CBT) for insomnia and anxiety. Their prescription products, SleepioRx and DaylightRx, serve health systems, health plans, and employers with evidence-based mental health solutions backed by 100+ peer-reviewed publications.
Blueprint Health
Blueprint provides an AI-powered assistant for mental health therapists that automates clinical documentation, generates treatment plans, and delivers clinical support. The platform works alongside existing EHRs or as a standalone AI-native EHR with integrated scheduling, telehealth, billing, and insurance management.
Boulder Care
Boulder Care provides telehealth-based addiction treatment for substance use disorder (SUD), including opioid use disorder (OUD) and alcohol use disorder (AUD). The company delivers whole-person, coordinated outpatient care through a secure mobile app, including medication-assisted treatment (MAT) with Suboxone and other medications, supported by dedicated care teams.
Brightline
Brightline is an award-winning pediatric mental health practice providing expert therapy, psychological testing, and psychiatry services to children and teens up to age 18. The company offers both in-person care at clinics in New York and online services across NY, NJ, CT, MA, and WA.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.